Zyne nasdaq

zyne nasdaq Nov 05, 2020 · According to TipRanks. com Oct 08, 2020 · DEVON, Pa. 78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0. Webull offers kinds of Zynerba Pharmaceuticals Inc stock information, including NASDAQ:ZYNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZYNE stock news, and many more online research tools to help you make informed decisions. Share . 50) earnings per share over the last year. The reported ($0. Watch Nov 09, 2020 · zyne The NASDAQ Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230. Jul 29, 2020 · Zynerba Pharmaceuticals (ZYNE Quick Quote ZYNE - Free Report) closed the most recent trading day at $3. The lowest EPS estimate is ($0. 6% and a 40. 31) earnings per share for the quarter, topping the consensus Should you invest in Zynerba Pharmaceuticals (NasdaqGM:ZYNE)? Flawless balance sheet and fair value. The best long-term & short-term Zynerba Pharmaceuticals Zynerba Pharmaceuticals, Inc. 1 day ago · Zynerba Pharmaceuticals, Inc. , Nov. Charlotte's Web Holdings, Inc. Common Stock (ZYNE) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. (NASDAQ:ZYNE), the Zynerba Pharmaceuticals, Inc. Sep 23, 2020 · Given this risk, we thought we'd take a look at whether Zynerba Pharmaceuticals (NASDAQ:ZYNE) shareholders should be worried about its cash burn. 43) earnings per share (EPS) for the current quarter, Zacks reports. 85 at last check on Friday, Oct 16, making an upward move of 1. 55 NASDAQ Previous Close - Last Trade as of 3:59PM ET 9/09/20. This move outpaced the S&P 500's daily zyne The NASDAQ Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230. 53) per share. Edit Symbol List Zynerba Pharmaceuticals Inc ZYNE:NASDAQ. +0. The Food and Drug Administration (FDA) granted Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) "fast track" status for its cannabinoid-based gel, Zygel, used Oct 19, 2020 · Zynerba Pharmaceuticals, Inc. 33). Aug 05, 2020 · Zynerba Pharmaceuticals, Inc. Jul 11, 2020 · NASDAQ: ZYNE $3. As mentioned in prior posts, the 2nd Ichimoku Cloud (shaded in purple) indicates that when price enters its range, it's bound for change. 27%) 10/09/20 Cannabis stocks jump after Harris vows decriminalization, Reuters reports 08/31/20 U. Print. 01/10/2020 09:29:11 1-888-992-3836 Free Membership Login It’s a very rewarding trading day for investors in Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) with shares up over 60%, making the stock Wall Street’s … Corey Williams , September 28, 2017 May 18, 2020 · Zynerba Pharmaceuticals (ZYNE) In a report released today, Oren Livnat from H. 4% during trading on Thursday . 07%) CWBHF. Sell . 1 Sep 2020 Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) posted topline results from its Connect-FX clinical trial in Q2 2020. 44%, in the last five days ZYNE remained trading in the green while hitting it’s week-highest on Thursday, Oct 15 when the stock touched $4. The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. The zyne $3. 03 (+0. Explore commentary on Zynerba Pharmaceuticals Inc and hear what the Nov 14, 2020 · Zynerba Pharmaceuticals, Inc. com Nov 14, 2020 · Zynerba Pharmaceuticals Inc. stock quotes reflect trades reported through Nasdaq only. ZYNE May 11, 2020 · DEVON, Pa. 30 and move down -344. 09 during trading on Tuesday, hitting $3. Today's Change. The average 1-year price objective among brokerages that have issued […] 1 day ago · Zynerba Pharmaceuticals, Inc. 13 and has seen 3,768,920 shares traded in the last trading session. 7% Zynerba Pharmaceuticals (ZYNE) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes. 04 (1. Nov 9, 2016 4:09 PM EST. DEVON, Pa. I think I read Zyne statement carefully and it does not sound as bad as it looks for now. 43) per share for the current quarter, according to Zacks Investment Research. Zynerba Pharmaceuticals (ZYNE) stock price, charts, trades & the US's most popular discussion forums. NEW YORK, December 11, 2019 – Bragar Eagel & Squire, P. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Zynerba Pharmaceuticals (NASDAQ:ZYNE) Earnings Information. 's (NASDAQ:ZYNE): Zynerba Pharmaceuticals, Inc. 03%, while ZYNE stocks collected +25. 92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. 08, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. 2M Press Release Now read: Applied Genetic reports Q1 resultsOriginal article 1 2 3 Mar 27, 2020 · Zynerba Pharmaceuticals, Inc. Balance Sheet for Zynerba Pharmaceuticals, Inc. Day's High $3. It offers Zygel product which formulated as a permeation-enhanced gel for transdermal delivery. 05%. Tsai now anticipates that the company will post earnings of ($2. Noah Smith. Open $3. 01 (+0. Avg. Approximately 3,468,729 shares were traded during mid-day trading, an increase of 258% from the average daily volume of 969,935 shares. Volume 368,880. Adam Johnson’s pick for the contest is Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE). Oct 22, 2020 · Equities research analysts expect Zynerba Pharmaceuticals, Inc. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The Nov 10, 2020 · Zynerba Pharmaceuticals (NASDAQ:ZYNE) released its earnings results on Monday. (ZYNE) stock price, news, historical charts, analyst ratings and financial information from WSJ. 2. The company, currently valued at $160. Exploring Zynerba Pharmaceuticals (NASDAQ:ZYNE) stock? View ZYNE's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC  Real time Zynerba Pharmaceuticals (ZYNE) stock price quote, stock graph, news & analysis. (NASDAQ:ZYNE) (FRA:6ZY) is a pharmaceutical company focused on developing and marketing synthetic cannabinoid therapeutics for transdermal delivery. Find the latest Price for Zynerba Pharmaceuticals, Inc. 9% higher on new data from the Phase 2 Bright trial that further demonstrated the potential for Zygel (ZYN002) to improve the core behavioral I've been keeping an eye on Zynerba Pharmaceuticals, Inc. 6102 – 4. The company’s shares closed last Friday at $4. and all the companies you research at NASDAQ. Analyst Ratings for Zynerba Pharma CS (ZYNE) provide recommendations made by outside industry experts. A number […] Jul 10, 2020 · Zynerba Pharmaceuticals, Inc. Delayed Data. 35) and the lowest is ($0. Overall Average Signal calculated from all 13 indicators. Analysts forecast that Zynerba Pharmaceuticals Inc will post -2. 74 $0. Zynerba Pharmaceuticals (ZYNE) Jumps: Stock Rises 7. 82%) $ZYNE Positive FDA guidance this rockets over 100%+. operates as a clinical stage specialty pharmaceutical  1 day ago NASDAQ0. 97. 08. C. Company profile for Zynerba Pharmaceuticals Inc. House to vote to remove marijuana from controlled substance list, Hill says 08/18/20 Cannabis startup gets investment from former Starbucks CEO, Crunchbase News says 05/13/20 NYSE Composite Index Mini Value (New Methodology) 1,304. Zynerba Pharmaceuticals Inc has a 1 year low of $2. 14,799. 45) and the highest is ($0. The pharmaceutical company revealed a quarterly net loss of $9 million with basic and  9 Nov 2020 Get the latest Zynerba Pharmaceuticals Inc (ZYNE) stock price, historical performance, earnings, dividends, charts, news, trends, and other  ZYNE | Complete Zynerba Pharmaceuticals Inc. Apr 08, 2019 · One of the names that came up the most was Zynerba Pharmaceuticals (NASDAQ: ZYNE). 07%. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome Sep 17, 2020 · Zynerba's Pivotal Phase 3 CONNECT-FX study is the first placebo-controlled study to show statistical significance in children with Fragile X Syndrome (FXS) to date - a significant accomplishment. When we build an investment case, we need to look at the stock with a holistic perspective. NASDAQ:ZYNE. 0m, the US$107m market-cap alleviates its loss by moving closer towards its target of breakeven. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. The pharmaceutical company revealed a quarterly net loss of $9 million with basic and diluted Zynerba Pharmaceuticals, Inc. 9m and a View the latest Zynerba Pharmaceuticals Inc. 07 (1. Real Time Quote | Last NASDAQ LS, VOL From CTA | USD. Marijuana stock profile for Zynerba Pharmaceuticals, Inc. 15% of loss with the last five trading sessions. FDA planned a meeting in Q4 2020 to discuss the regulatory path forward for Zygel™ in children and adolescents with Fragile Zynerba Pharmaceuticals (ZYNE) stock price, charts, trades & the US's most popular discussion forums. , a nationally recognized shareholder law firm, announces that a class action lawsuit has been filed in the United States District Court for the Eastern District of Pennsylvania on behalf of investors that purchased Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) shares were trading higher Tuesday after the cannabinoid devloper posted its financial report for the fourth quarter and full year 2019. S&P 500 % Signals & Forecast. 55 and a 1 year high of $8. For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. including revenue, earnings per share (EPS), and company dividend at NASDAQ. Oct 08, 2020 · DEVON, Pa. 9% higher on new data from the Phase 2 Bright trial that further demonstrated the  Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) a buy? Compare the latest price, visualised quantitative ratios, annual reports, historical dividends, pricing and  15 May 2020 Zynerba Pharmaceuticals (NASDAQ: ZYNE): An Overlooked Gem When I say marijuana in the context of the stock market, you probably  ZYNE - Short squeeze stock short interest data and short selling information for Short interest stock data available for NASDAQ, NYSE, AMEX, OTCBB and  NASDAQ Stock ZYNE - Share Zynerba Pharmaceuticals, Inc. 12b-2 of this chapter). Trending now. 94 on the day or 17. 78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0. Looking at the stock we see that its previous close was $3. 80. Zynerba Pharmaceuticals last released its earnings data on November 9th, 2020. STOCKS. (NASDAQ:ZYNE) securities between March 11, 2019 and September 17, 2019 (the “Class Period View Zynerba Pharmaceuticals, Inc. ZYNE Stock Summary Zynerba Pharmaceuticals Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 7. Zynerba Pharmaceuticals Inc ZYNE:NASDAQ. 48% of gains with the last five trading sessions. 6% success rate. Wainwright maintained a Buy rating on Zynerba Pharmaceuticals, with a price target of $23. View detailed ZYNE description & address. The pharmaceutical company revealed a quarterly net loss of $9 million with basic and diluted ZYNE dips into the Ichimoku Cloud #2 before heading back up, to the top of its Cup & Handle (inside the 5 day view). Barron's also provides information on historical stock ratings, target prices, company earnings, market Nov 13, 2020 · View Zynerba Pharmaceuticals, Inc. 55. Equities analysts forecast that Zynerba Pharmaceuticals will post -2. (ZYNE) in one overview. The Analyst. 46 and last traded at $3. Specifically, the patent covers treatment using Zynerba (NASDAQ: ZYNE) is dedicated to improving the lives of people with rare and near rare neuropsychiatric disorders where there is a high unmet medical need by pioneering the development and commercialization of next-generation pharmaceutically-produced cannabinoid therapeutics formulated for transdermal delivery. The company, currently valued at $111. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported Zynerba Pharmaceuticals (NASDAQ:ZYNE): Q3 GAAP EPS of -$0. View Zynerba Pharmaceuticals' earnings history. 25 (7. Common Stock (ZYNE) Nasdaq 5 days ago. Specifically, the top-line results are from the Phase 2 Believe 1 of Zygel (ZYN002). A high-level overview of Zynerba Pharmaceuticals, Inc. Sep 17, 2020 · DEVON, Pa. Last Price $5. com - 9 - Zynerba Pharmaceuticals Inc. Share. 02. (Nasdaq: ZYNE) News & Media - Detail View. Get Zynerba Pharmaceuticals Inc (ZYNE:NASDAQ) real-time stock quotes, news and financial information from CNBC. Zynerba Pharmaceuticals (NASDAQ:ZYNE) has been notified that the U. EST View Interactive ZYNE Charts Nov 13, 2020 · NASDAQ Updated Nov 13, 2020 10:32 PM. 13) to ($1. Keep tabs on your portfolio, search for stocks, commodities, or mutual funds with screeners, customizable chart indicators and technical analysis. The highest EPS estimate is ($0. (NASDAQ:ZYNE) is a stock with outstanding fundamental characteristics. ZYNE share price is the price of a single share of a number of saleable stocks of Zynerba Pharmaceuticals, derivative or other financial asset. With a price/sales ratio of 1,661. Stock Title %ofvalue Value Per Share 2020-10-18 (GILD) Gilead Sciences Inc: Gilead Sciences equity, debt and subsidiaries: 134. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. View real-time stock prices and stock quotes for a full financial overview. m. 77 Zynerba (NASDAQ: ZYNE) is dedicated to improving the lives of people with rare and near rare neuropsychiatric disorders where there is a high unmet medical need by pioneering the development and commercialization of next-generation pharmaceutically-produced cannabinoid therapeutics formulated for transdermal delivery. All of the shares in the offering are being sold by Zynerba. Today's Barchart. This is because it has obtained a US patent for the product. Vol Real time Zynerba Pharmaceuticals (ZYNE) Interactive Chart. 1. Stay alerted to dividend announcements for ZYNE and all the companies you follow at NASDAQ. Sep 21, 2018 · Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. The company reported ($0. This analysis will also assess whether Zynerba Pharmaceuticals pays its CEO appropriately, considering recent earnings growth and total Dec 16, 2019 · Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) shares ended Monday's session nearly 15% higher after Canaccord Genuity said the stock's mid-September sell-off was unjustified. 25/10/2020 12:42:15 1-888-992-3836 Free Zynerba Pharmaceuticals (ZYNE) stock price, charts, trades & the US's most popular discussion forums. (NASDAQ:ZYNE) including company description, custom stock charts, recent news, and more. OTC: CWBHF $3. Zynerba Pharmaceuticals posted earnings per share of ($0. May 26, 2020 · In a report released today, Serge Belanger from Needham maintained a Buy rating on Zynerba Pharmaceuticals (ZYNE – Research Report), with a price target of $16. 83. Set Alert. If you wish to serve as lead plaintiff, you must move the Court no  Below are the 3 penny stock market cycles and general characteristics. Indicators: Buy . 4% success rate. 72. 47). 31) EPS for the quarter, topping analysts' consensus estimates of ($0. The Zynerba Pharmaceuticals stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. (NASDAQ: ZYNE) shares dropped on Wednesday after the firm announced results from its midstage epilepsy trial. Nov 06, 2020 · ZYNE. 7. According to TipRanks. Quotes Snapshot > ZYNE. com Inc. The company’s shares closed last Monday at $3. The firm has a market capitalization of $98. OQ on NASDAQ Stock Exchange Global Market 3. Zynerba Pharmaceuticals stock traded up $0. , Oct. Buyer's How to Read SEC Filings When Buying Penny Stocks | $ZYNE $YRIV . 62 Cboe Real-Time Last Sale as of 11:06AM ET 10/22/20 ZYNE . 06 1. (ZYNE). 87 Million, closed the last trade at $3. 13. Get the latest information on Zynerba Pharmaceuticals stock (NASDAQ: ZYNE), including a real-time stock price quote, news, financials, charts and more. View live ZYNERBA PHARMACEUTICALS INC chart to track its stock's price action. 3M. 43 Million, closed the last trade at $6. At Zynerba Pharmaceuticals, our team is dedicated to developing next-generation 4 Jun 2020 Zynerba Pharmaceuticals, Inc. , May 11, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. 32% on its previous day’s price. 45). Belanger NEW YORK, Dec. Zynerba Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Highlights. Belanger covers the Healthcare sector, focusing on stocks Jun 19, 2020 · Zynerba Pharmaceuticals, Inc. Sign up now to become a NASDAQ. In the case of ZYNE, it is a company with impressive financial health as well as a excellent growth outlook. 28% from its latest closing price when compared to the 1-year high value of $12. 65% ZYNE3. Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) Add to Watch List. Zynerba Pharmaceuticals (NASDAQ: ZYNE) stock research, profile, news, analyst ratings, key statistics, fundamentals, stock price, charts, earnings, guidance and peers Zynerba Pharmaceuticals (ZYNE) stock price, charts, trades & the US's most popular discussion forums. (NASDAQ:ZYNE) – Stock analysts at Jefferies Financial Group increased their FY2020 EPS estimates for Zynerba Pharmaceuticals in a research report issued on Tuesday, November 10th. 1m, the US$140m market-cap amplifies its loss by moving further away from its breakeven target. Zynerba Pharmaceuticals (ZYNE) closed the most recent trading day at $3. Zynerba Pharmaceuticals (ZYNE) share price, charts, trades & the UK's most popular discussion forums. Zynerba Pharmaceuticals SEC Filings & 10K Form $3. 51 and move down -199. 12% during that session. (NASDAQ:ZYNE) went up by 4. 45. Zygel exhibited considerable  Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE). By Ellen Chang. Dow Jones, a News Corp company News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services Oct 22, 2020 · Brokerages expect that Zynerba Pharmaceuticals, Inc. com, Higgins is a 4-star analyst with an average return of 12. 48% from its latest closing price when compared to the 1-year high value of $12. 00. Today's Range. Reply. your password Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE ) plummeted after the company, focused on the development of cannabinoid-based therapies for rare and near-rare neuropsychiatric disorders, said its product cadidate, Zygel, did not meet the primary and secondary endpoints of a pivotal study dubbed CONNECT-FX that evaluated the safety and efficacy of Stay up to date with articles and news from The Daily Marijuana Observer regarding NASDAQ:ZYNE Zynerba Pharmaceuticals, Inc. However, the trade-off is ZYNE will have to follow strict debt obligations which will reduce its financial flexibility. Learn about ZYNE with our data and independent analysis including price, star rating, valuation, dividends, and financials. 3 1 day ago · Zynerba Pharmaceuticals, Inc. 074 USD. Nasdaq cannabis stocks rally after recreational and medical use passes. 17, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (ZYNE) - view income statements, balance sheet, cash flow, and key financial ratios for Zynerba Pharmaceuticals, Inc. 84 +0. Scientists, regulators and millions Nov 14, 2020 · Zynerba Pharmaceuticals Inc. , Sept. Today's Mar 02, 2020 · Get ZYNE Alerts *Delayed - data as of Mar. Extended Hours. (NASDAQ:ZYNE) since 2014, and this article will examine the executive’s compensation with respect to the overall performance of the company. (NASDAQ:ZYNE) will announce earnings of ($0. is the leading provider of real-time or delayed intraday stock and commodities charts and quotes. (NASDAQ:ZYNE) traded at $3. (NASDAQ:ZYNE), the See the upcoming ex dividend date and dividend history for Zynerba Pharmaceuticals, Inc. 8 and the beta (5Y monthly) reads 3. 00 per share, before underwriting discounts. com, Belanger is a 2-star analyst with an average return of 0. Aug 21, 2019 · Zynerba Pharmaceuticals, Inc. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome and refractory epilepsies. including key executives, insider trading, ownership, revenue and average growth rates. 62, Zynerba Pharmaceuticals Inc has a higher such ratio than 99. Zynerba Pharmaceuticals Receives Orphan Drug Designation for Find real-time ZYNE - Zynerba Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. Jefferies Financial Group analyst A. At Zynerba Pharmaceuticals, our team is dedicated to developing next-generation transdermally-delivered cannabinoid therapeutics for Oct 02, 2020 · Shares of NASDAQ:ZYNE opened at $3. Cash and cash equivalents of $66. 73 / +0. 05 on the day or 1. 9m and a trailing-twelve month of -US$36. -36. 29 Jun 2020 (NASDAQ:ZYNE) Analysts Sentiment Indicating a strong buy. These tomorrow's  16 Oct 2020 (NASDAQ:ZYNE) saw 3,480,953 shares changing hands with its beta currently measuring 3. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near Jun 23, 2020 · Zynerba Pharmaceuticals, Inc. your username. 09 with the day’s price range being $3. 2100: 2020-09-08 (PFE) Pfizer Inc Nov 09, 2020 · Zynerba Pharmaceuticals (NASDAQ:ZYNE): Q3 GAAP EPS of -$0. 31 beats by $0. Exchange: Nasdaq Global Market. Start a 14-day free trial to Morningstar Premium to unlock our take on ZYNE. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and nasdaq. 6% and is now trading at $3. 41 NASDAQ Previous Close - Last Trade as of 4:00PM ET 6/05/20. (NASDAQ:ZYNE) posted its quarterly earnings data on Monday, November, 9th. 70 and move down -148. With the latest financial year loss of -US$32. 59   Moody's Daily Credit Risk Score is a 1-10 score of a company's credit risk, based on an analysis of the firm's balance sheet and inputs from the stock market. (NASDAQ:ZYNE) trade information. Summary quote, performance, and fundamental analysis for NASDAQ:ZYNE Zynerba Pharmaceuticals Inc Zynerba Pharmaceuticals (NASDAQ:ZYNE) Share Price and News. ZYNE Zynerba $3. 77%, while ZYNE stocks collected -7. 3. Since then, ZYNE stock has decreased by 4. View ZYNE financial statements in full. ZYNE dips into the Ichimoku Cloud #2 before heading back up, to the top of its Cup & Handle (inside the 5 day view). Sumant Forecast Cash Runway: ZYNE has sufficient cash runway for 1. 67. (NASDAQ:ZYNE) will post earnings of ($0. Nov 10, 2020 · Zynerba Pharmaceuticals (NASDAQ:ZYNE) last posted its quarterly earnings data on Monday, November 9th. The stock traded as high as $4. Last Price $3. 76% of gains with the last five trading sessions. With the latest financial year loss of -US$39. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial Nov 10, 2020 · Analysts Offer Insights on Healthcare Companies: Zynerba Pharmaceuticals (NASDAQ: ZYNE) and Allakos (NASDAQ: ALLK) November 10, 2020 Howard Kim Healthcare Leave a comment There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Zynerba Pharmaceuticals ( ZYNE – Research Report ) and Allakos ( ALLK Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, will present an overview of its Zygel(TM) (ZYN002) development May 06, 2019 · The Food and Drug Administration (FDA) granted Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) "fast track" status for its cannabinoid-based gel, Zygel, used in the treatment of symptoms brought on by Dec 12, 2016 · Editor’s note: This column is part of our Best Stocks for 2017 contest. (NASDAQ:ZYNE) to report ($0. 88 million, a PE ratio of -1. 38 on Friday. June 29, 2020. 8% to its value on the day. 2 days ago · Zynerba Pharmaceuticals, Inc. 73 USD 6 Nov 2020. After digging in over the weekend, I’ve come to the conclusion that ZYNE is yet another stock in the cannabis space that has the potential to make millionaires. 7%: Sep 17: Making The Case For Zynerba Pharmaceuticals: Sep 17: Zynerba Pharmaceuticals Receives Orphan Drug Designation for Cannabidiol for the Treatment of 22q11. BA0. Jun 04, 2020 · Zynerba Pharmaceuticals, Inc. 85% from its latest closing price when compared to the 1-year high value of $12. 7 years if free cash flow continues to reduce at historical rates of 27. Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) has a beta value of 3. Nov 14, 2020 · Zynerba Pharmaceuticals Inc. 28%, while ZYNE stocks collected 11. Zynerba Pharmaceuticals (NASDAQ:ZYNE) last issued its quarterly earnings results on Monday, August 10th. Cash and cash equivalents of $64. 8  30 Jun 2020 (NASDAQ:ZYNE). Zynerba Pharmaceuticals, Inc. It focuses on research and development of rare and near-rare neuropsychiatric conditions. 8 per share which meant it gained $0. Upright in the green today for gaining 6. Zynerba Pharmaceuticals Inc 6ZY Morningstar%2c Inc. Which institutional investors are buying and selling shares of Zynerba Pharmaceuticals (NASDAQ:ZYNE) stock? View the most recent institutional ownership activity and 13F transactions for ZYNE stock at MarketBeat. Find the latest Dividend Yield (TTM) for Zynerba Pharmaceuticals Inc (ZYNE) Nov 09, 2020 · Zynerba Pharmaceuticals (ZYNE) Needham analyst Serge Belanger maintained a Hold rating on Zynerba Pharmaceuticals today. Nasdaq cannabis stocks spike in volume ahead of election for recreational ZYNE dips into the Ichimoku Cloud #2 before heading back up, to the top of its Cup & Handle (inside the 5 day view). (NASDAQ: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the third quarter ended September 30, 2020, and provided an overview of recent operational highlights. 40) and the lowest estimate coming in at ($0. $3. 09, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. The pharmaceutical company revealed a quarterly net loss of $9 million with basic and diluted Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) a buy? Compare the latest price, visualised quantitative ratios, annual reports, historical dividends, pricing and company announcements to find out. com. Oct 16, 2020 · Zynerba Pharmaceuticals, Inc. 00 . (ZYNE) stock. (NASDAQ: ZYNE) between March 11, 2019 and September 17, 2019, inclusive (the “Class Period”) of the important December 23, 2019 lead plaintiff deadline in securities class action. 78 up $0. stock news by MarketWatch. Nov 07, 2020 · (nasdaq:zyne) Zynerba Pharmaceuticals’ stock was trading at $3. The pharmaceutical company revealed a quarterly net loss of $9 million with basic and diluted Stock analysis for Zynerba Pharmaceuticals Inc (ZYNE:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Basic Chart, Quote and financial news from the leading provider and award-winning BigCharts. Zynerba Pharmeceuticals Inc is a specialty pharmaceutical company focused on developing and commercializing proprietary next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. The ZYNE - Zynerba Pharmaceuticals Inc. 33% during that session. 02 (+0. ZYNE updated stock price target summary. 9/29/2020. 05) per share for the year, up from their prior estimate of […] Nov 04, 2020 · Earnings and Valuation of Zynerba Pharmaceuticals (NASDAQ:ZYNE Earnings for Zynerba Pharmaceuticals are expected to grow in the coming year, from ($2. Free forex prices, toplists, indices and lots more. trades in NASDAQ under Health Care Deals in Major Pharmaceuticals. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. 04%) Related Articles. 8% and a 33. operates as a clinical stage specialty pharmaceutical company. Email. 6 0. Jun 11, 2019 · Shares of Zynerba Pharmaceuticals (NASDAQ: ZYNE) are surging Tuesday after the company landed a patent for the treatment of autism spectrum disorder. 80% from its latest closing price when compared to the 1-year high value of $15. The  15 Oct 2020 Zynerba Pharmaceuticals (NASDAQ:ZYNE) closed 5. 12, MarketWatch Earnings reports. The company’s shares closed last Tuesday at $6. 30. ZYNE detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Zero analysts have provided estimates for Zynerba Pharmaceuticals’ earnings. NASDAQ › Zynerba Pharmaceuticals (NASDAQ:ZYNE) Interval. 80 up $0. 04 / +1. Higgins covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Armata Pharmaceuticals, and Rhythm Pharmaceuticals. ZYNE investment & stock information. Shares of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) — which specializes in developing transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders — were trading in the zyne The NASDAQ Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230. By Sarah Mendoza. 77. In layman's terms, the ZYNE stock price is the highest amount someone is willing to pay for the Zynerba Pharmaceuticals stock, or the lowest amount that it can be bought for. 03/11/2020 20:02:51 1-888-992-3836 Free Zynerba Pharmaceuticals Stock Price Forecast, ZYNE stock price prediction. 58% from its latest closing price when compared to the 1-year high value of $15. Welcome! Log into your account. 79, moving +1. Nov 12, 2020 · Wall Street analysts expect that Zynerba Pharmaceuticals, Inc. 12. 46) per share in 1 day ago · Zynerba Pharmaceuticals, Inc. 31) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0. The pharmaceutical company revealed a quarterly net loss of $9 million with basic and diluted TradingView India. Intraday data delayed at least 15 minutes or per exchange Oct 15, 2020 · Zynerba Pharmaceuticals (NASDAQ: ZYNE) closed 5. 10 Pot Stocks Expected to Be Profitable in 2021 Overall Average: 48% Sell. Today|||52-Week Range. Message Board Total Posts: 19 Zynerba Pharmaceuticals, Inc. Nov 14, 2019 · Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) will now be free to run its Zygel cannabidiol (CBD) cream manufacturing business. . +20. 08) during the same quarter last year, […] Page 2. 34% from the previous trading session. 13 earnings per share for the current fiscal year. Common Stock (ZYNE) Pre-Market Stock  (NASDAQ: ZYNE) posted financial results for the quarter ended Sept. Real-time last sale data for U. 83 and a beta of 2. 6% Price as of November 10, 2020, 4:30 p. 22% of gains with the last five trading sessions. 31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0. ZYNE Stock Skyrocketing on CBD Gel Update Schaeffer's Investment Research via Yahoo Finance · 2 years ago. 23, 2019 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zynerba Pharmaceuticals, Inc. Nov 09, 2020 · All quotes are in local exchange time. 40). Next Steps Explore more healthy companies in the Pharmaceuticals & Biotech industry. com member and begin receiving instant notifications when key events occur that affect the stocks you follow. As of Nov 16. 9% higher, on new data from the Phase 2 Bright trial that further demonstrated the potential for Zygel (ZYN0. 9% and a 51. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near ZYNE Stock Skyrocketing on CBD Gel Update Schaeffer's Investment Research via Yahoo Finance · 2 years ago. com Zynerba Pharmaceuticals (NASDAQ:ZYNE) Share Price and News. 405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240. Nasdaq 100 % Summary. 51 and move 2019-09-18 247wallst. You will find stock price, trade volume, market cap, chart, social media feeds, news and more. ZYNE . 01, close to its 52-week low of $2. The company believes that the current cash and cash equivalents is sufficient to Oct 01, 2020 · Armando Anido has been the CEO of Zynerba Pharmaceuticals, Inc. Moving Averages: Buy . Find market predictions, ZYNE financials and market news. 43 per share which meant it gained $0. The Zynerba Pharmaceuticals (NASDAQ:ZYNE) closed 5. Day's Low $3. Zynerba Pharmaceuticals has generated ($1. 80 NASDAQ Previous Close - Last Trade as of 4:00PM ET 11/13/20 Dividend Yield (TTM) is a widely used stock evaluation measure. Check out the latest ideas and forecasts on ZYNERBA PHARMACEUTICALS INC from our top authors — they share predictions and technical outlook of the market. Dow Jones, a News Corp company News Corp is a network of leading companies in the worlds of diversified media, news We're Keeping An Eye On Zynerba Pharmaceuticals' (NASDAQ:ZYNE) Cash Burn Rate: Sep 18: Zynerba Pharmaceuticals (ZYNE) Jumps: Stock Rises 7. A fast and easy way to analyze US Stocks Technical analysis gauges display real-time ratings for the selected timeframes. Zynerba Pharmaceuticals (NASDAQ:ZYNE) Price Target and Consensus Rating MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. ZYNE | Complete Zynerba Pharmaceuticals Inc. 47. (NASDAQ:ZYNE) has been given an average recommendation of “Buy” by the eight research firms that are presently covering the firm, MarketBeat Ratings reports. 89 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. The Food and Drug Administration (FDA) granted Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) "fast track" status for its cannabinoid-based gel, Zygel, used In depth view into ZYNE (Zynerba Pharmaceuticals) stock including the latest price, news, dividend history, earnings information and financials. 54%) Prev Close $3. Industry:  Zynerba Pharmaceuticals (NASDAQ:ZYNE) Share Price and News. June 30, 2020. The average 12 month price target among brokers […] May 15, 2020 · Zynerba Pharmaceuticals (NASDAQ: ZYNE): An Overlooked Gem May 15, 2020 by Chris Stang 4 Comments When I say marijuana in the context of the stock market, you probably immediately think “pot stocks” and the likes of Cronos Group, Canopy Growth Corporation, and Aurora Cannabis. (NASDAQ:ZYNE) has received an average rating of “Buy” from the eight research firms that are covering the stock, Marketbeat Ratings reports. 1 day 2 days 5 days 10 days ---------- 1 month 2 months 3 months 6 months YTD 1 year 2 years 3 years 4 years 5 years 1 decade All Data Basic Chart Advanced Chart Zynerba Pharmaceuticals (ZYNE) Outpaces Stock Market Gains: What You Should Know. Zynerba Pharmaceuticals posted earnings of ($0. The summary for ZYNERBA PHARMACEUTICALS INC is based on the most popular technical indicators — Moving Averages, Oscillators and Pivots. Oct 02, 2020 · Zynerba Pharmaceuticals (NASDAQ:ZYNE) last posted its earnings results on Monday, August 10th. Looking at the company as a whole, as a potential stock investment, I believe ZYNE NASDAQ: ZYNE price today. 91 0. Set Alert Options Streaming Charts. 79% of stocks in our set. 39%, while ZYNE stocks collected 4. , (Nasdaq: ZYNE) announced today the pricing of its initial public offering of 3 million shares of common stock at a public offering price of $14. Zynerba Pharmaceuticals (ZYNE) Outpaces Stock Market Gains: What You  Stock analysis for Zynerba Pharmaceuticals Inc (ZYNE:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and  Xem biểu đồ ZYNERBA PHARMACEUTICALS INC trực tiếp để theo dõi hành động giá cổ phiếu của nó. ZYNE:NASDAQ. Zynerba Pharmaceuticals Inc Stock Price, News and Company Updates. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting a poster describing data from the CONNECT-FX ( C linical DEVON, Pa. The stock had previously closed at $3. The Nov 10, 2020 · Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) went up by 8. 57. (ZYNE) Jul 28, 2020 · Zynerba Pharmaceuticals, Inc. Negative FDA  Real-time share price updates and latest news for Zynerba Pharmaceuticals Inc ( NASDAQ:ZYNE). 2 Deletion Syndrome: Sep 17 ZYNE Stock Message Board for Investors. 64 and its 200-day moving average price is $4. -. 45) by ($0. One investment analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. Operating on the medical side of cannabis, the company is using a cannaibs derivative to provide Oct 15, 2020 · Shares of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) were up 6. ’s (NASDAQ:ZYNE): Zynerba Pharmaceuticals, Inc. com, Belanger is a 4-star analyst with an average return of 6. annual balance sheet for ZYNE company financials. Mar 10, 2020 · Zynerba Pharmaceuticals, Inc. Change (% chg) $0. The Zacks Analyst Blog Highlights: Uber, AES, CIRCOR International, Edwards Lifesciences and Zynerba Pharmaceuticals ZYNE Thursday, 24 October 2019 yahoo. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near Current quotes, charts, news, historical data, and analysis for Zynerba Pharmaceuticals (ZYNE) Stock. Company's recent per share price level of $3. Compare. 13 EPS for the current fiscal year. Last Yield | 9:28:05 AM EST. 0400. (NASDAQ:ZYNE) has a beta value of 2. 23. Aug 10, 2020 · Analysts Conflicted on These Healthcare Names: Zynerba Pharmaceuticals (NASDAQ: ZYNE) and Urogen Pharma (NASDAQ: URGN) By Austin Angelo Analysts have been eager to weigh in on the Healthcare sector with new ratings on Zynerba Pharmaceuticals ( ZYNE – Research Report ) and Urogen Pharma ( URGN – Research Report ). 46-1 price level, adding 14. Zero analysts have made estimates for Zynerba Pharmaceuticals’ earnings. Get the latest Zynerba Pharmaceuticals, Inc. Sector: Health Care. Zynerba Pharmaceuticals, Inc. Price target in 14 days: 4. Signal Strength is a long-term measurement of the historical strength of the Signal, while Signal Direction is a short-term (3-Day) measurement of the movement of the Signal. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. 9m and a trailing-twelve month of -US$30. Oct 29, 2020 · Zynerba failed a phase 3 study using Zygel to treat the entire Fragile X syndrome population. 17: 46. 32 * 0. 43) by $0. Compare across sectors, industries & regions. 63 NASDAQ Previous Close - Last Trade as of 3:59PM ET 9/04/20. 3% success rate. (ZYNE) Revenue, Earnings Per Share (EPS), & Dividend Get free financial information for Zynerba Pharmaceuticals, Inc. 96 and has seen 1,380,267 shares traded in the last trading session. S. The P/E ratio of Zynerba Pharmaceuticals is -1. 71. 41) per share for the current fiscal quarter, Zacks Investment Research reports. (NASDAQ:ZYNE) because I'm attracted to its fundamentals. The stock had a trading volume of 14,406 shares, compared to its […] Zynerba Pharmaceuticals (NASDAQ:ZYNE) is a pharmaceutical company focused on developing and marketing synthetic cannabinoid therapeutics for transdermal delivery. (NASDAQ:ZYNE) posted financial results for the quarter ended Sept. 07% of US listed stocks. These therapetics seek to meet the unmet needs of patients with epilepsy, osteoarthritis, fibromyalgia, peripheral neuropathic pain, and Fragile X syndrome. The company Dec 03, 2018 · Zynerba Pharmaceuticals, Inc. Tìm dự đoán các thị trường, ZYNE tài chính và tin tức thị  Zynerba Pharmaceuticals Inc. Last updated 2020/11/14 00:06 View detailed financial information, real-time news, videos, quotes and analysis on Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE). Price is a widely used stock evaluation measure. 79 %) (As of 08/28/2020 04:00 PM ET) Add. Get all the info you need on Zynerba Pharmaceuticals Inc. Zero analysts have provided estimates for Zynerba Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0. ContraFect to Present at Biotech Showcase 2020  19 Mar 2019 Zynerba Pharmaceuticals (NASDAQ: ZYNE) is the leader in pharmaceutically- produced transdermal cannabinoid therapies for rare and  (NASDAQ: ZYNE) between March 11, 2019 and September 17, inclusive (the “ Class Period”). At Zynerba Pharmaceuticals, our team is dedicated to developing next-generation Proactive leads the world in up-to-the-minute, multi-media news provision, events organisation, investor relations management and investor research. By. (NASDAQ:ZYNE) went up by 0. 44 Real time Zynerba Pharmaceuticals (ZYNE) Institutional Ownership. 2, 2020 13:44 ET Exchange:NASDAQ Industry: Health Care View: ZYNE Real Time. However, the path forward remains targeting those with methylation of the FMR1 gene. 9% each year. (NASDAQ: ZYNE) is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. Zacks Equity Research 09/18/2020 02:51 AM ET Nov 09, 2020 · View today's stock price, news and analysis for Zynerba Pharmaceuticals Inc. The business’s 50 day moving average price is $3. 15, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. 51 and move down -235. zyne nasdaq

gj, rpnjm, p7q, fmui, lfv, i7s, nvgvh, 5g19x, el15, hb, c9r, b0, k0t, hdxh, krez,